CSL and Vitaeris Inc have announced they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab, an anti-IL6 MAB, formerly ALD518, as a therapeutic option for solid organ transplant rejection.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 06 Dec 17
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 17
